Search results for "lymphocyte count"

showing 10 items of 140 documents

Patterns of transmitted HIV drug resistance in Europe vary by risk group

2014

BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM…

MaleEpidemiologygenotypeHuman immunodeficiency virus 1HIV InfectionsRNA directed DNA polymerase inhibitorhigh risk patientLogistic regressionSettore MED/42 - Igiene Generale E ApplicataMen who have sex with men0302 clinical medicineImmunodeficiency Virusesmiddle agedstatistics and numerical data10. No inequalitySubstance Abuse Intravenous0303 health sciencesadulttransmissionvirus diseasesvirus transmissionhighly active antiretroviral therapyHIV immunopathogenesis3. Good healthMedical MicrobiologyViral Pathogenshigh risk behaviorMedicineScience & Technology - Other TopicsPOPULATIONShealth programanti human immunodeficiency virus agentUSERSmedicine.medical_specialtyScienceSexual BehaviorImmunologySexually Transmitted Diseasesintravenous drug abuse-Microbiology03 medical and health sciencesAntibiotic resistanceSDG 3 - Good Health and Well-beingHuman immunodeficiency virus infectionproteinase inhibitorHumansProtease InhibitorshumanHeterosexualityMicrobial PathogensseroconversionMedicine and health sciencesScience & TechnologyGenitourinary InfectionsMUTATIONSVirologymajor clinical studyLogistic Modelstransmitted drug resistance mutationHeterosexualityHIV-1Viral Diseases:Medical sciences: 700::Basic medical dental and veterinary sciences: 710::Medical immunology: 716 [VDP]drug responsemen who have sex with menDrug resistanceClinical immunologygeographyAPPEARANCEmale homosexualityMedizinische Fakultätimmune system diseasesEpidemiologyINFECTIONMedicine and Health Sciencessubstance abuse030212 general & internal medicineriskMultidisciplinaryACTIVE ANTIRETROVIRAL THERAPYTransmission (medicine)virus mutationQRarticleObstetrics and GynecologyHIV diagnosis and managementMiddle AgedvirologyMultidisciplinary SciencesEuropeInfectious Diseasesfemale:Medisinske fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 [VDP]Reverse Transcriptase InhibitorsHIV clinical manifestationsFemaleepidemiologyblood samplingHIV drug resistanceResearch ArticleAdultRiskrisk-groupAnti-HIV AgentsUrologyprevalenceInfectious Disease Epidemiologysexual behaviorRisk-Takingmaleantiviral resistanceInternal medicineDrug Resistance Viralmedicinecontrolled studyddc:610Homosexuality Male030304 developmental biologydrug resistanceBiology and life sciencesbusiness.industrystatistical modelHIVCD4 lymphocyte countheterosexualitynonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionDiagnostic medicineINDIVIDUALSdrug effectsWomen's Healthbusinesstrend study
researchProduct

Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2021

BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 10 9 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.DESIGN: Multinational prospective cohort study.SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included…

MaleHIV AIDSHIV Infections0302 clinical medicineInterquartile rangeRisk FactorsNeoplasmsMedicine030212 general & internal medicineProspective StudiesProspective cohort study0303 health sciencesIncidenceAbsolute risk reductionDrugsGeneral MedicineMiddle AgedViral LoadAntiretroviral therapy3. Good healthAIDSCancer treatmentPrevention policy and public healthCohortInfectious diseasesCohort studiesFemaleViral loadAdultmedicine.medical_specialtyAnti-HIV AgentsHIV Infections/drug therapySocio-culturaleTime-to-Treatment03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingInternal medicineInternal MedicineHumansAdverse effect030306 microbiologybusiness.industryHIVCancermedicine.diseaseCD4 Lymphocyte CountCancer.Anti-HIV Agents/therapeutic use[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessNeoplasms/epidemiologyAnnals of Internal Medicine
researchProduct

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

2011

An investigation was undertaken to determine whether specific pol mutations hinder long-term immune recovery regardless of virological response. In total, 826 patients with >50 HIV RNA copies/ml, who underwent genotypic resistance testing between 1 January 2000 and 31 December 2003 after >3 years of antiretroviral treatment, and were followed up for >3 years after genotypic resistance testing, were analyzed retrospectively. The outcome of the study was the lack of immune recovery after >3 years of follow-up, defined as a slope by linear regression 50 copies/ml divided by the number of HIV RNA measurements during follow-up. Logistic regression was used for univariable and multivariable analy…

MaleHIV InfectionsDrug resistanceLogistic regressionResistance to nucleoside reverse transcriptase inhibitorCD4+ T-lymphocyteRetrospective StudieImmunopathologyAntiretroviral Therapy Highly ActiveResistance to non-nucleoside reverse transcriptase inhibitorgeneticsResistance to protease inhibitorHIV Infectionresistance to nucleoside reverse transcriptase inhibitorsViralSidaresistance to protease inhibitorsbiologyReverse-transcriptase inhibitorViral LoadGenes poldrug therapy/immunology/virologyReverse Transcriptase InhibitorInfectious DiseasesTreatment Outcomeresistance to non-nucleoside reverse transcriptase inhibitorsReverse Transcriptase InhibitorsFemaleViral loadmedicine.drugHumanpolAnti-HIV AgentsAntiretroviral TherapyViremiaInfectious DiseaseSettore MED/17 - MALATTIE INFETTIVEpharmacology/therapeutic useAcquired immunodeficiency syndrome (AIDS)VirologyDrug Resistance ViralmedicineHumansHighly ActiveRetrospective StudiesAnti-HIV Agents; pharmacology/therapeutic use Antiretroviral Therapy; Highly Active CD4 Lymphocyte Count Drug Resistance; Viral; genetics Female Genes; pol HIV Infections; drug therapy/immunology/virology HIV-1; drug effects/enzymology/genetics Humans Male Mutation Retrospective Studies Reverse Transcriptase Inhibitors; therapeutic use Treatment Outcome Viral Loaddrug resistanceAnti-HIV Agentbiology.organism_classificationmedicine.diseaseVirologyCD4 Lymphocyte CountGenesdrug effects/enzymology/geneticstherapeutic useMutationCD4+ T-lymphocytesHIV-1
researchProduct

In vitro anticholinergic drugs affect CD8+ peripheral blood T-cells apoptosis in COPD

2011

Novel pharmacological strategies are aimed at the resolution of systemic inflammation in COPD potentiating peripheral blood T-cell (PBT-cell) apoptosis. Although muscarinic acetylcholine receptors (mAChRs) M(3) and choline-acetyltransferase (ChAT) participate in the airway inflammation of COPD, their role in PBT-cell apoptosis remains unexplained. We evaluated in PBT-cells from COPD patients, smoker (S) and control (C) subjects: (1) apoptosis (by annexin V binding), (2) mAChR M(3) and ChAT expression, acetylcholine (ACh)-binding; (3) choline levels in serum and PBT-cells extracts. We tested the effects of Tiotropium (Spiriva(®)) and hemicholinium-3 (HCh-3) on apoptosis, NFκB pathway, caspas…

MaleImmunologyScopolamine DerivativesApoptosisCD8-Positive T-LymphocytesPharmacologySystemic inflammationCholinergic AntagonistsCholineCholine O-AcetyltransferasePulmonary Disease Chronic ObstructiveAnnexinMuscarinic acetylcholine receptormedicineHumansImmunology and AllergyLymphocyte CountTiotropium BromideCaspaseAgedReceptor Muscarinic M3Caspase 8COPDbiologyCaspase 3Systemic inflammation Non-neuronal components of cholinergic system Caspases NF B pathwaybusiness.industryNF-kappa BHematologyTiotropium bromideMiddle Agedmedicine.diseaserespiratory tract diseasesEnzyme ActivationApoptosisbiology.proteinFemalemedicine.symptombusinessAcetylcholineProtein BindingSignal Transductionmedicine.drugImmunobiology
researchProduct

Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromes

2009

Abstract Background Low lymphocyte count (LLC), a surrogate for inflammation, has emerged as a potential risk factor for cardiovascular outcomes, especially new ischemic events. To identify patients with non-ST segment elevation acute coronary syndromes (NSTEACS) who benefit from an invasive revascularization strategy remains a challenge. We sought to determine if patients with high-risk NSTEACS who exhibited LLC have a greater reduction in long-term post-discharge myocardial infarction (MI) when managed under a revascularization invasive strategy (RIS) as compared with conservative strategy (CS). Methods Nine hundred seventy two consecutive patients with high-risk NSTEACS were treated unde…

MaleInvasive strategymedicine.medical_specialtyLymphocytemedicine.medical_treatmentMyocardial InfarctionRevascularizationElectrocardiographyRisk FactorsLymphopeniaInternal medicineMyocardial RevascularizationInternal MedicineHumansMedicineST segmentLymphocyte CountMyocardial infarctionAcute Coronary SyndromeLow lymphocyte countAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelPrognosismedicine.diseaseTreatment Outcomemedicine.anatomical_structureQuartileCardiologyFemalebusinessEuropean Journal of Internal Medicine
researchProduct

Association of γδ T Cells with Disease Severity and Mortality in Septic Patients

2013

ABSTRACTGamma-delta T cells are the most abundant of all epithelial-resident lymphocytes and are considered a first line of defense against pathogens in the mucosa. Our objective was to confirm the reduction in γδ T cell subsets and its relationship with mortality in patients with sepsis. We studied 135 patients with sepsis attended in the emergency department and intensive care unit of two hospitals and compared them with a similar control group of healthy subjects. The αβ and γδ T cell subsets were determined via flow cytometry according to the stage of the sepsis and its relationship with mortality. All the lymphocyte subsets were reduced with respect to the corresponding subsets in the …

MaleMicrobiology (medical)CD3 ComplexReceptors Antigen T-Cell alpha-betaCD3T cellClinical BiochemistryImmunologylaw.inventionFlow cytometrySepsisDisease severityT-Lymphocyte SubsetslawSepsismedicineHumansImmunology and AllergyIn patientLymphocyte CountAgedbiologymedicine.diagnostic_testHealthy subjectsReceptors Antigen T-Cell gamma-deltaMiddle Agedmedicine.diseaseIntensive care unitCD56 Antigenmedicine.anatomical_structureImmunologybiology.proteinFemaleClinical ImmunologyClinical and Vaccine Immunology
researchProduct

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

2013

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.

MaleMultivariate analysisDatabases FactualDrug ResistanceHIV InfectionsDrug resistance0302 clinical medicineRetrospective StudieRisk FactorsEpidemiologyGenotypepol Gene Products Human Immunodeficiency ViruOdds RatioPrevalenceImmunology and AllergyHIV Infection030212 general & internal medicinepol Gene ProductsViralMultivariate Analysimedia_common0303 health sciencesDrug Resistance Prevalence HIV-1Middle AgedResistance mutation3. Good healthReverse Transcriptase InhibitorEuropeInfectious DiseasesReverse Transcriptase InhibitorsepidemiologyFemaleMultipleHuman Immunodeficiency VirusHumanDrugAdultmedicine.medical_specialtyGenotypeEvolutionmedia_common.quotation_subjectSexual Behaviorantiretroviral therapyInfectious DiseaseBiologySettore MED/17 - MALATTIE INFETTIVEEvolution Molecular03 medical and health sciencesDatabasesSDG 3 - Good Health and Well-beingDrug Resistance Multiple ViralmedicineHumansHIV Protease InhibitorFactualRetrospective Studies030306 microbiologyRisk FactorMolecularRetrospective cohort studyOdds ratioHIV Protease InhibitorsCD4 Lymphocyte Countantiretroviral therapy; drug resistance; epidemiology; genotyping; HIV-1; Adult; CD4 Lymphocyte Count; Databases Factual; Europe; Evolution Molecular; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sexual Behavior; pol Gene Products Human Immunodeficiency Virus; Drug Resistance Multiple Viral; Immunology and Allergy; Infectious Diseasesgenotypingpol Gene Products Human Immunodeficiency VirusImmunologyMultivariate AnalysisMutationHIV-1DemographyJournal of Infectious Diseases
researchProduct

Behaviour of the neutrophil to lymphocyte ratio in young subjects with acute myocardial infarction

2016

In the last years the neutrophil to lymphocyte ratio (NLR) has been examined in cardiovascular disorders and in particular in coronary artery disease and acute myocardial infarction (AMI). Now we examined this parameter in subjects with juvenile myocardial infarction at the initial stage and after 3 and 12 months. We enrolled 123 young subjects (112 men and 11 women, mean age 39.4 ± 5.8 yrs) with AMI. The time interval between the AMI onset and the investigation was 13 ± 7 days. The mean value of NLR observed in young AMI subjects was significantly increased compared to normal controls (N = 1.817 ± 0.711; young AMI subjects = 2.376 ± 0.873, p <  0.0001). NLR does not discriminate STEMI (2.4…

MaleNeutrophilsPhysiologyLymphocyteMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyCoronary artery diseaseLeukocyte Count0302 clinical medicineRetrospective StudieRisk FactorsMedicineLymphocytes030212 general & internal medicineMyocardial infarctionStage (cooking)HematologyNeutrophilSmokingJuvenile myocardial infarction; leukocyte count; neutrophil/lymphocyte ratio; Adult; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female; Humans; Inflammation; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Myocardial Infarction; Neutrophils; Prognosis; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Smoking; Physiology; Hematology; Cardiology and Cardiovascular Medicine; Physiology (medical)HematologyMiddle AgedPrognosismedicine.anatomical_structureAbsolute neutrophil countCardiologyLymphocyteFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyPrognosi03 medical and health sciencesPhysiology (medical)Internal medicineHumansLymphocyte Countcardiovascular diseasesNeutrophil to lymphocyte ratioRetrospective StudiesInflammationbusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseJuvenile myocardial infarctionneutrophil/lymphocyte ratioST Elevation Myocardial InfarctionbusinessBiomarkersClinical Hemorheology and Microcirculation
researchProduct

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.

2013

Bevacizumab is a humanized anti-VeGF monoclonal antibody able to produce clinical beneit in advanced non-squamous non-small cell lung cancer (nsCLC) patients when combined to chemotherapy. At present, while there is a rising attention to bevacizumab-related adverse events and costs, no clinical or biological markers have been identiied and validated for baseline patient selection. preclinical indings suggest an important role for myeloid-derived inlammatory cells, such as neutrophils and monocytes, in the development of VeGF-independent angiogenesis. We conducted a retrospective analysis to investigate the role of peripheral blood cells count and of an inlammatory index, the neutrophil-toly…

MaleOncologyCancer ResearchLung NeoplasmsNeutrophilsmedicine.medical_treatmentPlatinum CompoundsMonocyteCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsNeutrophil-to-lymphocyte ratioUnivariate analysisadvanced non-small cell lung cancerMiddle AgedBevacizumabAngiogenesiTreatment OutcomeOncologyMolecular MedicineFemalemedicine.symptomLung cancermedicine.drugmedicine.medical_specialtyBevacizumabInflammationAntibodies Monoclonal HumanizedDisease-Free SurvivalInternal medicinemedicineHumansLymphocyte CountNeutrophil to lymphocyte ratioLung cancerAdverse effectAgedNeoplasm StagingRetrospective StudiesPharmacologyInflammationChemotherapyBedside to Bench ReportPlatelet Countbusiness.industryRetrospective cohort studymedicine.diseaseMultivariate AnalysisImmunologybusinessSystemic inflammatory status
researchProduct

ROC-king onwards: intraepithelial lymphocyte counts, distribution & role in coeliac disease mucosal interpretation

2017

ObjectivesCounting intraepithelial lymphocytes (IEL) is central to the histological diagnosis of coeliac disease (CD), but no definitive ‘normal’ IEL range has ever been published. In this multicentre study, receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off between normal and CD (Marsh III lesion) duodenal mucosa, based on IEL counts on &gt;400 mucosal biopsy specimens.DesignThe study was designed at the International Meeting on Digestive Pathology, Bucharest 2015. Investigators from 19 centres, eight countries of three continents, recruited 198 patients with Marsh III histology and 203 controls and used one agreed protocol to count IEL/100 ent…

MalePathologySettore MED/09 - Medicina Interna2312ROC-curve analysiBiopsyCoeliac diseaseSerology0302 clinical medicineintraepithelial lymphocytesDiagnosis80 and overROC-curve analysis; coeliac disease; intraepithelial lymphocytes1506LymphocytesIntestinal MucosaChild1507medicine.diagnostic_testArea under the curveGastroenterologyhemic and immune systemsMiddle AgedPrognosis030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemalemedicine.symptomtissuesAdultmedicine.medical_specialtyAdolescentchemical and pharmacologic phenomenaBiologydigestive systemLesion03 medical and health sciencesBiopsymedicineHumansLymphocyte CountPreschoolAgedReceiver operating characteristicInfantHistologymedicine.diseaseNewbornROC-curve analysis; coeliac disease; intraepithelial lymphocytes; Adolescent; Adult; Aged; Aged 80 and over; Biopsy; Case-Control Studies; Celiac Disease; Child; Child Preschool; Diagnosis Differential; Female; Humans; Infant; Infant Newborn; Intestinal Mucosa; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Prognosis; ROC Curve; GastroenterologyCeliac DiseaseROC CurveCase-Control StudiesDifferentialIntraepithelial lymphocyteROC-curve analysiscoeliac disease
researchProduct